TrialThe oncologist2018

Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma.

Harry Yoon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.